Novonesis Past Earnings Performance
We're still processing the latest earnings report of this company
Past criteria checks 0/6
Novonesis's earnings have been declining at an average annual rate of -1.3%, while the Chemicals industry saw earnings growing at 9.6% annually. Revenues have been growing at an average rate of 8.1% per year. Novonesis's return on equity is 2.6%, and it has net margins of 9.3%.
Key information
-1.3%
Earnings growth rate
-0.6%
EPS growth rate
| Chemicals Industry Growth | 12.4% |
| Revenue growth rate | 8.1% |
| Return on equity | 2.6% |
| Net Margin | 9.3% |
| Next Earnings Update | 26 Feb 2025 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Novonesis makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 3,045 | 283 | 575 | 326 |
| 31 Mar 24 | 2,696 | 332 | 506 | 298 |
| 31 Dec 23 | 2,401 | 406 | 446 | 271 |
| 30 Sep 23 | 2,390 | 430 | 441 | 270 |
| 30 Jun 23 | 2,382 | 460 | 446 | 272 |
| 31 Mar 23 | 2,390 | 487 | 441 | 270 |
| 31 Dec 22 | 2,360 | 494 | 430 | 267 |
| 30 Sep 22 | 2,268 | 460 | 443 | 262 |
| 30 Jun 22 | 2,186 | 418 | 418 | 257 |
| 31 Mar 22 | 2,090 | 416 | 403 | 257 |
| 31 Dec 21 | 2,009 | 423 | 380 | 266 |
| 30 Sep 21 | 1,958 | 427 | 335 | 268 |
| 30 Jun 21 | 1,914 | 409 | 322 | 274 |
| 31 Mar 21 | 1,883 | 389 | 310 | 270 |
| 31 Dec 20 | 1,883 | 380 | 309 | 256 |
| 30 Sep 20 | 1,920 | 415 | 309 | 248 |
| 30 Jun 20 | 1,955 | 405 | 326 | 254 |
| 31 Mar 20 | 1,968 | 439 | 335 | 264 |
| 31 Dec 19 | 1,924 | 422 | 329 | 263 |
| 30 Sep 19 | 1,923 | 411 | 334 | 262 |
| 30 Jun 19 | 1,917 | 434 | 321 | 260 |
| 31 Mar 19 | 1,922 | 417 | 315 | 249 |
| 31 Dec 18 | 1,927 | 432 | 313 | 248 |
| 30 Sep 18 | 1,924 | 427 | 311 | 254 |
| 30 Jun 18 | 1,915 | 429 | 310 | 247 |
| 31 Mar 18 | 1,920 | 423 | 320 | 248 |
| 31 Dec 17 | 1,952 | 419 | 332 | 255 |
| 30 Sep 17 | 1,958 | 421 | 334 | 255 |
| 30 Jun 17 | 1,934 | 412 | 332 | 254 |
| 31 Mar 17 | 1,919 | 414 | 328 | 251 |
| 31 Dec 16 | 1,902 | 410 | 325 | 251 |
| 30 Sep 16 | 1,864 | 394 | 327 | 247 |
| 30 Jun 16 | 1,883 | 394 | 333 | 253 |
| 31 Mar 16 | 1,883 | 384 | 331 | 259 |
| 31 Dec 15 | 1,876 | 378 | 330 | 254 |
| 30 Sep 15 | 1,840 | 366 | 320 | 255 |
| 30 Jun 15 | 1,795 | 353 | 314 | 252 |
| 31 Mar 15 | 1,741 | 340 | 311 | 243 |
| 31 Dec 14 | 1,673 | 339 | 306 | 237 |
| 30 Sep 14 | 1,641 | 334 | 314 | 227 |
| 30 Jun 14 | 1,605 | 324 | 310 | 216 |
| 31 Mar 14 | 1,598 | 319 | 312 | 211 |
| 31 Dec 13 | 1,575 | 295 | 311 | 205 |
Quality Earnings: NZM has a large one-off loss of €105.1M impacting its last 12 months of financial results to 30th June, 2024.
Growing Profit Margin: NZM's current net profit margins (9.3%) are lower than last year (19.3%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: NZM's earnings have declined by 1.3% per year over the past 5 years.
Accelerating Growth: NZM's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: NZM had negative earnings growth (-38.5%) over the past year, making it difficult to compare to the Chemicals industry average (5%).
Return on Equity
High ROE: NZM's Return on Equity (2.6%) is considered low.